1-3 of 3
Doris Mangelberger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tafasitamab in Combination with a CD20xCD3 Bispecific T-Cell Engager Significantly Prolongs Survival in Preclinical Lymphoma Models

Eveline Schaadt, Christina Heitmüller, Solveig Peters, Kristina Ilieva, Derek Blair, Christiane Huth, Dominik Bartel, Sandra Zapf, Markus Eberl, Doris Mangelberger-Eberl, Frank Giles, Carsten Corvey
Journal: Blood
Blood (2023) 142 (Supplement 1): 2813.
https://doi.org/10.1182/blood-2023-188574
Published: 2023
Journal Articles

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Alexander Biedermann, Doris Mangelberger-Eberl, Dimitrios Mougiakakos, Maike Büttner-Herold, Cindy Flamann, Christian Kellner, Sarah Altmeyer, Jörg Bittenbring, Christian Augsberger, Maria Patra-Kneuer, Karin Landgraf, Kristina Ilieva-Babinsky, Stefan Haskamp, Fabian Beier, Simon Voelkl, Christian Pallasch, Benedikt Jacobs, Stefan Steidl, Christina Heitmüller, Andreas Mackensen, Heiko Bruns
Journal: Blood
Blood (2022) 140 (Supplement 1): 9292–9293.
https://doi.org/10.1182/blood-2022-159955
Published: 2022
Journal Articles

Blockade of the CD47/SIRPα Checkpoint Potentiates the Anti-Tumor Efficacy of Tafasitamab

Doris Mangelberger, Christian Augsberger, Karin Landgraf, Christina Heitmüller, Stefan Steidl
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-139582
Published: 2020